International Clinical Trial: A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07464535) titled 'A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects' on March 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Tonix Pharmaceuticals, Inc.

Condition: Healthy Subjects (HS)

Intervention: Drug: TNX-102 SL

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 18, 2022

Target Sample ...